NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 18 hours 30 min ago

Role of Peripheral Proteostasis on Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed)

Wed, 10/25/2017 - 10:58
Funding Opportunity RFA-AG-18-020 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimers Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.
Categories: NIH-Funding

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)

Wed, 10/25/2017 - 10:40
Funding Opportunity PAR-18-329 from the NIH Guide for Grants and Contracts. This Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).
Categories: NIH-Funding

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)

Wed, 10/25/2017 - 10:40
Funding Opportunity PAR-18-326 from the NIH Guide for Grants and Contracts. This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).
Categories: NIH-Funding

Understanding the Early Development of the Immune System (R01 - Clinical Trial Not Allowed)

Wed, 10/25/2017 - 10:04
Funding Opportunity PAR-18-333 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support studies on the very early development of the immune system and the humoral and cellular communication that exists between the mother and fetus that may shape or impact immune system development and maturation.
Categories: NIH-Funding

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

Wed, 10/25/2017 - 03:00
Funding Opportunity PAR-18-406 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement phase II and beyond investigator-initiated single-site clinical trials. Applications submitted to this FOA must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.
Categories: NIH-Funding

Enhancing Central Neural Control of Mobility in Aging (U01 Clinical Trial Optional)

Wed, 10/25/2017 - 02:09
Funding Opportunity RFA-AG-18-019 from the NIH Guide for Grants and Contracts. The overall goal of this funding announcement is to solicit applications to investigate the central neural control of mobility in older adults without overt neurological diseases using innovative and cutting-edge methods that are emerging in neuroscience, geriatrics and mobility-related fields in aging research communities. This announcement also seeks information on the degree of plasticity in the aging brain and how this may be harnessed to maintain or improve mobility. Applicants are highly encouraged to adapt a multidisciplinary and collaborative approach that includes basic, clinical, and translational scientists. Mobility impairments are common in aging and are associated with a host of adverse events including disability and mortality. Identifying novel modifiable predictors of mobility decline will lead to mechanistic insights and the development of novel therapeutic interventions to enhance mobility as a person ages.
Categories: NIH-Funding

Reminder: FORMS-E Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2018

Tue, 10/24/2017 - 12:33
Notice NOT-OD-18-009 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Request for Information (RFI) on Enhancing Utilization of the NIH Clinical Center

Tue, 10/24/2017 - 12:19
Notice NOT-OD-18-007 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Technical Assistance Webinar for Human Heredity and Health in Africa (H3Africa) RFAs: RFA-RM-17-020, RFA-RM-17-021

Tue, 10/24/2017 - 04:03
Notice NOT-RM-18-001 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Change in the Due Date for PAR-17-458 "Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01)"

Mon, 10/23/2017 - 12:55
Notice NOT-DA-17-055 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Building Research Capacity in Global Tobacco Product Regulation Program (U18)

Fri, 10/20/2017 - 12:50
Funding Opportunity RFA-FD-18-003 from the NIH Guide for Grants and Contracts. The Food and Drug Administration announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program. The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDAs exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTPs) mission by utilizing the World Health Organizations (WHO) Member States expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States. The Program will also provide a universal public benefit by creating opportunities for collaboration and research development globally, thereby resulting in better-informed and effective tobacco product regulation around the world, and increased knowledge in the public sphere regarding tobacco use and its harms globally.
Categories: NIH-Funding

Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)

Fri, 10/20/2017 - 12:32
Funding Opportunity RFA-CA-17-044 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers. The DRSCs are designed to target the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Establish a network of multi-disciplinary research teams to study mechanisms of tumor resistance and sensitivity and develop innovative anti-cancer therapy strategies. The Coordinating Center to be established under this FOA will facilitate the activities of the DRSCs and help integrate the results of their studies.
Categories: NIH-Funding

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3)

Fri, 10/20/2017 - 12:18
Funding Opportunity RFA-CA-17-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.
Categories: NIH-Funding

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24)

Fri, 10/20/2017 - 12:18
Funding Opportunity RFA-CA-17-039 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.
Categories: NIH-Funding

Typical and Atypical Patterns of Language and Literacy in Dual Language Learners (R21-Clinical Trial Optional)

Fri, 10/20/2017 - 11:58
Funding Opportunity PA-18-328 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support investigator-initiated R21 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations.
Categories: NIH-Funding

Typical and Atypical Patterns of Language and Literacy in Dual Language Learners (R01-Clinical Trial Optional)

Fri, 10/20/2017 - 11:58
Funding Opportunity PA-18-316 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support investigator-initiated R01 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations.
Categories: NIH-Funding

NHLBI Program Project Applications (P01 - Clinical Trials Optional)

Fri, 10/20/2017 - 04:40
Funding Opportunity PAR-18-405 from the NIH Guide for Grants and Contracts. The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health disparities, and translation research that address the mission of the Institute. This FOA requires a minimum of three interrelated research projects that investigate a complex biomedical theme or research question. The projects may be supported by core units, if justified, to facilitate economy of effort, space, and equipment. The NHLBI provides support for Program Project Grants (PPGs) in the belief that collaborative research efforts can accelerate the acquisition of knowledge more effectively than a simple aggregate of research projects that have no interaction or thematic integration. NHLBI is particularly interested in encouraging new scientific directions in PPGs. Use of the P01 activity code is viewed as an opportunity to attract scientists who have not traditionally been supported by the NHLBI. Further, the PPG environment presents an opportunity for emerging scientific leaders to gain insight into how to lead a successful scientific Program, and applicants will have the opportunity to include a project led by an Early Stage Investigator (ESI). All projects in the Program must be interrelated and have objectives that address a central theme within the scientific mandate of the NHLBI.
Categories: NIH-Funding

Regional Technology Transfer Accelerator Hubs for IDeA States (STTR) (UT2 - Clinical Trial Not Allowed)

Fri, 10/20/2017 - 04:05
Funding Opportunity RFA-GM-18-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide opportunities for eligible U.S. small business concerns (SBCs), in collaboration with academic partners, to conduct research to develop, implement, and test a comprehensive program for promoting biomedical entrepreneurship, technology (tech) transfer, management, small business finance, and other business skills needed to move basic discoveries and technologies out of the lab and into commercial products that improve patient care and enhance human health. This would be done by regional tech transfer accelerator hubs created by the awardee SBCs in partnership with academic institutions in Institutional Development Award (IDeA) states (https://www.nigms.nih.gov/Research/CRCB/IDeA/Pages/default.aspx). Each accelerator hub program will be expected to serve a network of several institutional sites across the IDeA states in one of the four regions where the academic partners are located. The goal of this FOA is to enhance the capacity to move scientific results from academic institutions into commercialization and promote a sustainable culture of biomedical entrepreneurship within IDeA states. The product of the funded research will be educational tools i.e., curricula, texts, webinars resulting from the development and testing of research accelerator models. It is anticipated that the educational tools developed under this FOA will be licensed or sold to other institutions that wish to create accelerator hubs.
Categories: NIH-Funding